Translational Oncology

OCT 20, 2026 · JOURNAL ARTICLE

MSRB3 promotes gastric cancer progression and immunotherapy resistance by stabilizing GPX4 to inhibit ferroptosis

Translational Oncology

Methionine sulfoxide reductase B3 (MSRB3) possesses potent antioxidant activity and is highly expressed in various cancers, often correlating with poor prognosis. However, its biol

OCT 16, 2026 · JOURNAL ARTICLE

Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions

Translational Oncology

Mutation-based liquid biopsy supports diagnosis and disease monitoring in hematologic malignancies, but interpretation of plasma variants may be complicated by clonal hematopoiesis

OCT 14, 2026 · JOURNAL ARTICLE

NR3C2 suppresses triple-negative breast cancer progression by regulating mitochondrial ROS homeostasis via NDUFB3

Translational Oncology

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high molecular heterogeneity and a lack of effective targeted therapies. Increasing

OCT 1, 2026 · JOURNAL ARTICLE

A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis

Translational Oncology

Purpose Ovarian cancer (OC) is the second lethal gynecological malignancy, with chemoresistance being a major therapeutic challenge. Interestingly, although malignant ascites is ge

SEP 12, 2026 · JOURNAL ARTICLE

Role of CircRNA_0005075 in gastric cancer immune evasion through regulation of lactate metabolic reprogramming and histone lactylation

Translational Oncology

PURPOSE: Gastric cancer remains one of the most lethal malignancies worldwide. While immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have significantly advanced the trea

SEP 12, 2026 · JOURNAL ARTICLE

Salvage therapy for radiorecurrent prostate cancer: beyond equipoise – a call for biomarker-driven stratification

Translational Oncology

The increasing incidence of localized radiorecurrent prostate cancer demands a shift from modality-centric comparisons toward biomarker-driven patient selection. Light et al. provi

AUG 8, 2026 · REVIEW

Prediction models for adverse events from prostate cancer curative radiotherapy: a systematic review of methodological quality

Translational Oncology

Systematic review of prediction model quality showing most existing models have methodological limitations and lack external validation; identifies a gap rather than establishing a ready-to-use clinical tool.

AUG 7, 2026 · JOURNAL ARTICLE

Intercellular mitochondrial exchange shapes tumor evolution, microenvironment adaptation, and therapeutic vulnerabilities

Translational Oncology

A narrative review synthesizing mechanistic evidence on mitochondrial transfer in tumors; raises questions about therapeutic vulnerabilities but does not report original empirical results or clinical outcomes.